Is IBB a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,016 people get IBB articles and Market Currents by email alert.

Get email alerts on IBB »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Beat Obamacare With These Biotech ETFs
David Fabian • Mon, Apr 22 • 3 Comments
What's Growing Inside This Biotechnology ETF?
Henry Swann • Tue, Oct 9, 2012 • 2 Comments
Who Knows About The Bull Market In Biotech Stocks?
Rod Raynovich • Wed, Sep 26, 2012 • 2 Comments
Biotech ETFs In Focus: XBI Vs. IBB
David Fry • Wed, Apr 25, 2012 • 4 Comments
Big Pharma's Potential Consumer Growth Avenue
Jessica King Holden • Tue, Feb 7, 2012
The Giants, Ravens And 49ers Of Biotech
Jessica King Holden • Fri, Jan 20, 2012 • 14 Comments
Five ETFs to Let Run
Morningstar • Thu, Apr 29, 2010 • 2 Comments
Adding Leverage to an Already Volatile Sector: ProShares Launches 2x Long, Short Biotech ETFs
Invest With An Edge • Fri, Apr 9, 2010 • 1 Comment
Re-Evaluating Your Healthcare Exposure: A Sector ETF Overview
Morningstar • Thu, Mar 4, 2010
Biotech Breakout Confirmed
Bill Luby • Thu, Jul 31, 2008 • 3 Comments
iShares Biotech Index ETF: The Best Way to Invest in Biotech
Smart Profits Report • Wed, Apr 16, 2008
Biotech ETF's Diversity Reduces Risk
Tom Lydon • Thu, Jan 18, 2007
Basement Biotech: Threat to the Industry
Paul Kedrosky • Thu, Jun 22, 2006 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

Healthcare ETFs Will Perk Up Your Portfolio
John Dowdee • Mon, Jun 3 • 2 Comments
Bear Of The Day: Integra LifeSciences
Zacks Investment Research • Mon, Jun 3
Bull Of The Day: Salix Pharmaceuticals
Zacks Investment Research • Mon, Jun 3
2 Buys, 1 Sell In This Year's Biotech Surge
Richard Cox • Thu, May 30
What's Your Exit Strategy?
David Fabian • Wed, May 22 • 8 Comments
Positive Prognosis For Biotech ETFs
Tom Lydon • Mon, May 13
Why I Am A Biotech Permabull
EnhydrisPECorp • Tue, May 7 • 8 Comments
Playing To The Strengths Of Biotech
Richard Cox • Sat, Apr 13 • 6 Comments
Under The Hood: An Unheralded Biotech ETF
Benzinga • Thu, Apr 11 • 1 Comment
New Battleground Emerges For Dendreon Bulls And Bears
Brian L. Wilson • Mon, Apr 8 • 19 Comments
Check Out These Sectors For Q2 Upside
Todd Campbell • Tue, Apr 2 • 4 Comments
How To Assess Real-World Portfolio Diversification
John Dowdee • Mon, Apr 1 • 23 Comments
Gilead Sciences: Stribild Recommended, Great Long-Term Hold
Nick Chiu • Tue, Mar 26 • 3 Comments
When Do The Bears Admit They Are Wrong?
Bill Gunderson • Thu, Mar 21 • 30 Comments
Why Cyprus Does Matter
Bill Gunderson • Tue, Mar 19 • 5 Comments
2013 GDP Warning
Markos Kaminis • Thu, Feb 28 • 6 Comments
3 Stocks With Positive Upgrades And How To Invest
Nick Chiu • Thu, Feb 28
Biopharmaceutical Sector Attempts Another Move To New Highs
Rod Raynovich • Wed, Feb 27
3 Solid, Low Beta Biotechnology Stocks To Buy On Dip
Nick Chiu • Tue, Feb 26
Are Global Health Care ETFs Worth Prescribing?
Benzinga • Fri, Feb 22

There are no Transcripts on IBB.

Cramer's Checklist: 6 Bull Reversal 'Tells'

at CNBC.com (Jun 7, 2013)
Jeff Reeves's Strength in Numbers: 3 ways to play the biotech boom

at MarketWatch.com (Jun 3, 2013)
Slide Show: 11 insider plays that can bring you added income

at MarketWatch.com (May 21, 2013)
Investing in ‘junk DNA’

at MarketWatch.com (Sep 11, 2012)
The Technical Indicator: Charting the S&P 500’s resurgence

at MarketWatch.com (Jul 31, 2012)
The Technical Indicator: Charting the bull/bear battleground

at MarketWatch.com (Jul 17, 2012)
The Technical Indicator: Charting the bull/bear debate

at MarketWatch.com (Jul 3, 2012)
The Technical Indicator: Major U.S. benchmarks return to the range

at MarketWatch.com (Jun 19, 2012)
Stock Market Sell-Off Ahead? Fast Pros Watching These Signals

at CNBC.com (Jan 30, 2012)
Chuck Jaffe: How to buy stocks high and sell them low

at MarketWatch.com (Jul 1, 2011)
Money Talks: 5 money moves one market timer is making now

at MarketWatch.com (Jun 20, 2011)
Weekend Investor: 3 stock sectors to protect your portfolio now

at MarketWatch.com (May 20, 2011)
Biotech Mergers & More

at CNBC.com (Mar 30, 2011)
Skeptical of Rally? Dennis Gartman Says the Trend Is Up

at CNBC.com (Mar 30, 2011)
After Hours Action: Texas Instruments, Amgen...

at CNBC.com (Oct 25, 2010)
A Safer Biotech Play?

at CNBC.com (Jul 29, 2010)
Drug Giant Looking At Several Acquisitions

at CNBC.com (Jul 2, 2010)
Halftime Pt. 2: A Safer Play for a Volatile Market?

at CNBC.com (Jun 15, 2010)

IBB vs. ETF Alternatives

IBB Description

The iShares Nasdaq Biotechnology Index Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of companies primarily engaged in the biotechnology industry, as represented by the NASDAQ Biotechnology Index<sup>®</sup>.
See more details on sponsor's website

Sector: Healthcare

Country: United States

Key Info

In Your Portfolio: A Guide to Sector ETFs, A Guide to Healthcare, Pharma and Biotech ETFs
Asset Class Performance: Sectors

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
Thursday, April 11, 2:08 PM Healthcare and biotech ETFs continue to churn higher again today, hitting new 52-week highs across the board: Health Care SPDR (XLV +1%), Vanguard Health Care ETF (VHT +0.9%), iShares Dow Jones US Healthcare (IYH +0.9%),. Biotech ETF iShares NASDAQ Biotechnology Index (IBB +1.3%). 1 Comment [Healthcare, On the Move]
Thursday, March 28, 4:24 PM Biotech ETFs close at or near all-time highs as heavyweights Amgen (AMGN +2.4%), Biogen (BIIB +5.2%), Celgene (CELG +2.4%) and Gilead Sciences (GILD +2.5%) make new 52-week highs going into the holiday weekend. 1 Comment [Healthcare]
Monday, May 14, 2012, 11:45 AM Biotech ETFs are near all-time highs despite overall market weakness, due to successful trials - e.g. for Vertex's (VRTX) cystic fibrosis treatment - and because some investors are betting on deals occurring. One ETF that is doing particularly well this year is iShares Nasdaq Biotech (IBB). Others include XBI, FBT and BBH. 6 Comments [Healthcare]
Monday, March 12, 2012, 12:07 PM Shares of Anthera Pharmaceuticals (ANTH -52.1%) can't stop the freefall that was triggered by Friday's announcement that it's canceling its late-stage trial of its experimental treatment for heart disease. Adam Feuerstein eyes the recent carnage with a number of biotech names to conclude that "fail" is now re-entering the lexicon of investors in the sector. Comment! [On the Move, Healthcare, Quick Ideas]
Monday, January 23, 2012, 3:48 PM Part of J.P. Morgan's biotech (IBB -0.5%) cuts after the sector's recent run (I, II) include a move to Neutral from Overweight on Allos Therapeutics (ALTH +1.2%), noting that EU approval of its lymphoma drug looks at risk following last week's negative opinion from a European panel. Morgan's other calls lowered AMAG -6%, ACOR -0.5%, AMGN -2.5% and VPHM -2.4%. Comment! [Healthcare, On the Move]
Wednesday, January 18, 2012, 2:39 PM Josh Brown notices a "massive multi-year breakout" in biotech stocks (IBB +0.9%), with further gains likely as large pharmas continue to acquire the smaller firms so long as their own R&D departments are starving. "They have tons of cash and a burning desire to add pipeline - which makes almost every publicly-traded biotech a target for someone." Comment! [Healthcare]
Wednesday, September 7, 2011, 11:36 AM The biotech industry looks ripe for more gains after posting a second consecutive year of profits and seeing M&A activity heat up, says Karvy Global Services. Crunching the numbers reveals 8 stocks with implied upside potential based on quarterly results and analyst recommendations. Picks: HITK, CELG, DNDN, WX, TEVA, ILMN, CRL, BIIB. Comment! [Quick Ideas]
Thursday, August 4, 2011, 4:05 PM Dendreon (DNDN -67.4%) takes down an entire industry, with the Amex Biotech index falling an astonishing 10.4%. "Biotech risk takers burned on this one might be less risk tolerant going forward," one analyst explains. "The biotech group does work like that, especially for product failures." IBB -7.9%. XBI -9.8%. Comment! [Healthcare, On the Move, Top Stories]
Monday, June 27, 2011, 11:11 AM XOMA soars 33% after announcing the discovery of two new classes of fully human monoclonal antibodies at the American Diabetes Association 71st Scientific Sessions in San Diego. Comment! [Healthcare, On the Move]
Thursday, June 23, 2011, 4:17 PM Repligen's (RGEN +5%) jumps after its spinal muscular atrophy drug gets a fast-track designation from the FDA, and a postive opinion for orphan status from the European Medicines Agency. Comment! [Healthcare]
Wednesday, June 22, 2011, 9:52 AM Achillion Pharmaceuticals (ACHN +11.5%) jumps after pricing its secondary offering at $5.90, a 1.8% discount to yesterday's close. The company plans to use the $52M it raised to bring its new line of hepatitis-c drugs to market. Comment! [Healthcare, On the Move]
Monday, June 20, 2011, 4:20 PM Biogen-IDEC (BIIB +4.1%) closes at the top of the S&P leader board after ISI Group ups it to Buy, citing a strong pipeline, and noting its new BG-12 multiple-sclerosis pill can double earnings over the next three to four years. Comment! [Healthcare, On the Move]
Friday, June 17, 2011, 8:51 AM Vivus (VVUS) reports positive results for phase III testing of its erectile dysfunction drug Avanafil. The study is the last in a series to evaluate the drug's safety and efficacy in treating ED in patients who have undergone a radical prostatectomy. Shares +4% premarket. Comment! [Healthcare, On the Move]
Monday, March 7, 2011, 7:43 AM Sanofi (SNY) extends its offer for the outstanding shares of Genzyme (GENZ) to April 1 from March 16. Meanwhile, other biotech firms focused on rare diseases say the Sanofi-Genzyme deal puts many peers into play as takeover targets. Comment!
Saturday, October 30, 2010, 4:58 PM In a major policy reversal, the DoJ filed an amicus brief late yesterday saying human DNA and other genes shouldn't be eligible for patents. It's unclear whether the Patent Office will adopt the position, which could potentially force some biotech firms to change the way they develop drugs.
Comment!

Ypa Finance
$XLF is sector ETF #2 in our Tactical Allocation ranking. $IBB is #1. http://bit.ly/15ZIU78
Jun 13, 10:27 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Returning Upgrades (3/28/13): $CGNX, $CMG, $COO, $CP, $CPSI, $DIG, $DNB, $DST, $DTE, $ERX, $FBT, $GMT, $HES, $IBB, $IP, $IYT, $LSTR, $MIDD
Apr 1, 9:10 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Hypnos7
Biotech $IBB popping
Mar 28, 11:22 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Today's Potential Downgrades (3/18/13): $DISCA, $DO, $DSW, $ENR, $ETN, $EXPE, $GILD, $HOT, $HP, $IACI, $IBB, $IDCC, $IHS
Mar 19, 7:42 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dr. Kris
Bear alert! Several industry group etfs showing signs of overextension: Timber $CUT, Biotech ($FBT, $BBH, $IBB), Pharma ($PJP)...
Mar 5, 1:55 PM
Reply (2)

• !Report Abuse
View all 2 replies
Dr. Kris: If you're in any of these, you might want to start putting in a trailing (mental) stop/loss; lighten up; or protect position.
Mar 5, 1:56 PM
• !Report Abuse
Hillbilly Stock Star: They look like Panda Bears! LoL!
Mar 5, 1:58 PM
• !Report Abuse
Add a reply...

140 characters

Dr. Kris
Biotech looking anemic: After a great run, biotech etfs are stumbling. Breaking support today are $BBH, $IBB, $FBT.
10/31/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
3/21/12 2:05P ET: [ IBB ] When IBB hits $122, it's time to get short. Consider playing BIS. I continue to like this play at/below $24.
3/21/12
Reply (5)

• !Report Abuse
View all 5 replies
Justin M. Hall: It might require some work. We did very well with it last year. No BS. I like BIS right here and now.
3/22/12
• !Report Abuse
Justin M. Hall: [BIS] Going forward, I firmly believe it'll prove to be a solid bet. So, let's see how it plays out.
3/22/12
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
14 Stocks Gaining Momentum http://bit.ly/qsTj3m CBRL IAG IBB KS KSS LRCX MLHR MTN PEET QCOM RELL SMH TXN XLK
9/27/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
8/6/11 12A ET: (CBST, SPPI, IBB, BIS, XBI) BIOTECH CORRECTION Called in June 2011 => Were You Paying Attention? http://seekingalpha.com/p/4bsg
8/6/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
8/4/11 2:40P ET: BIOTECH CORRECTION Called Back in May-June 2011 [Rx Investors.com] (IBB, BIS, XBI, VRTX, DNDN) http://seekingalpha.com/p/4bsg
8/4/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Dr. Kris
Bear alert! Several industry group etfs showing signs of overextension: Timber $CUT, Biotech ($FBT, $BBH, $IBB), Pharma ($PJP)...
Mar 5, 1:55 PM
Reply (2)

• !Report Abuse
View all 2 replies
Dr. Kris: If you're in any of these, you might want to start putting in a trailing (mental) stop/loss; lighten up; or protect position.
Mar 5, 1:56 PM
• !Report Abuse
Hillbilly Stock Star: They look like Panda Bears! LoL!
Mar 5, 1:58 PM
• !Report Abuse
Add a reply...

140 characters

Justin M. Hall
3/21/12 2:05P ET: [ IBB ] When IBB hits $122, it's time to get short. Consider playing BIS. I continue to like this play at/below $24.
3/21/12
Reply (5)

• !Report Abuse
View all 5 replies
Justin M. Hall: It might require some work. We did very well with it last year. No BS. I like BIS right here and now.
3/22/12
• !Report Abuse
Justin M. Hall: [BIS] Going forward, I firmly believe it'll prove to be a solid bet. So, let's see how it plays out.
3/22/12
• !Report Abuse
Add a reply...

140 characters

IBB iShares Nasdaq Biotechnology ETF

IBB

iShares Nasdaq Biotechnology ETF